<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01043198</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2009/26</org_study_id>
    <nct_id>NCT01043198</nct_id>
  </id_info>
  <brief_title>Microarray Analysis in Syndromic Obesity</brief_title>
  <acronym>REMOB</acronym>
  <official_title>Phenotypic Characterization and Array CGH Analysis in Patients With Syndromic Obesity of Unknown Etiology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparative genomic hybridization (CGH) array technology has been used in numerous studies on
      mental retardation, and few chromosomal abnormalities have been identified in patients.
      Because chromosomal abnormalities have still been associated with obesity, we can expect that
      syndromic obesity is also associated with small deletions/duplications. Characterization of
      deleted or duplicated loci in these obese patients would mean that these loci include genes
      implicated in obesity. This will permit to propose new gene(s) involved in obesity. (In
      french: Caractérisation phénotypique et recherche de REManiements chromosomiques chez des
      patients présentant une OBésité syndromique de cause non identifiée : REMOB)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the introduction of array comparative genomic hybridization (CGH), genome-wide high
      resolution analysis for DNA copy number alterations became feasible. This technology has been
      principally used in patients with mental retardation. Depending on the eligibility criteria
      and resolution of the array, around 10 % of patients with mental retardation are found with
      cryptic chromosomal imbalance. This figure arises 20 % for patients with mental retardation
      and multiple congenital anomalies. Alteration of the lipid metabolism and/or regulation of
      satiety, obesity (except in presence of other &quot;exogen&quot; factors) can be considered as a
      developmental disorder. Also, different syndromes with obesity have been associated with
      chromosomal abnormalities, such as 1p36 deletion syndrome, 2q37 deletion syndrome, chromosome
      14 maternal disomy … So we can expect that syndromic obesity is similarly associated with sub
      cryptic chromosomal abnormalities. Some &quot;isolated&quot; patients with obesity have been described
      with cryptic chromosomal imbalance found by array CGH, but no study has been realized in
      cohorts of patients selected for syndromic obesity.

      Characterization of cryptic chromosomal anomaly(ies) in a patient will also be useful to
      precise the management and follow-up of the patient and to give the family an adapted genetic
      counselling.

      We will define a cohort of patients with syndromic obesity and propose them to realize a
      first screening looking for the &quot;common&quot; aetiologies of syndromic obesity. If this screening
      is normal, array CGH will be realized. This analysis implies a blood sampling of 5 ml in
      patient and his parents.

      Genes present at the deleted or duplicated loci characterized in the patients will be study
      to determine if some could be specifically implicated in the development of obesity. These
      same genes could be implicated in isolated obesity. Our study will be also useful to precise
      the aetiological screening of syndromic obesity, and determine the place of array-CGH.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the prevalence of cryptic chromosomal imbalance in patients with syndromic obesity of unknown etiology.</measure>
    <time_frame>3 - 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>prevalence of the main genetic aetiologies of syndromic obesity</measure>
    <time_frame>3 - 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of the main features evocative of subcryptic chromosomal anomalies in this population</measure>
    <time_frame>3 - 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phenotypic description of some &quot;new&quot; syndromes with obesity</measure>
    <time_frame>3 - 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>candidate genes implicated in the development of obesity.</measure>
    <time_frame>3 - 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delineation of an aetiological screening protocol in patients with syndromic obesity</measure>
    <time_frame>3 - 6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">90</enrollment>
  <condition>Mental Retardation</condition>
  <condition>Syndromic Obesity</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Clinical examination and blood sampling for biological and genetic analysis</intervention_name>
    <description>Clinical examination and precise description of the phenotype (questionnaire)
Standardized screening with :
radiological (hands, feet, spine ; and renal ultrasonography)
biological (hormonal, metabolic, and &quot;basic&quot; genetic investigations (karyotype, FISH 22q11.2, Fragile X, and other depending on the clinical data))</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  children (under 18 year-old)

          -  obesity (following IOTF definition)

          -  at least one criteria among :

               -  mental retardation

               -  facial dysmorphism

               -  at least one major malformation (uro-genital, cardiac, skeletal, cerebral,
                  ophthalmologic…)

        Exclusion Criteria:

          -  common obesity

          -  obesity with an identified aetiology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Ange DELRUE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Bordeaux, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Génétique de médicale - Hopital des enfants - Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Génétique Hôpital d'Enfants CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Génétique Médicale HOPITAL DEBROUSSE HCL</name>
      <address>
        <city>Lyon</city>
        <zip>69005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Département de Génétique Médicale Centre de référence anomalies du développement Centre de compétence maladies osseuses constitutionnelles Hôpital Arnaud de Villeneuve CHRU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Département de Génétique Hôpital Robert DEBRE Centre de Référence Maladies Rares &quot;Anomalies du Développement &amp; Syndromes Malformatifs&quot;</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital des Enfants, CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ. 2000 May 6;320(7244):1240-3.</citation>
    <PMID>10797032</PMID>
  </reference>
  <reference>
    <citation>Ichihara S, Yamada Y. Genetic factors for human obesity. Cell Mol Life Sci. 2008 Apr;65(7-8):1086-98. Review.</citation>
    <PMID>18097636</PMID>
  </reference>
  <reference>
    <citation>Delrue MA, Michaud JL. Fat chance: genetic syndromes with obesity. Clin Genet. 2004 Aug;66(2):83-93. Review.</citation>
    <PMID>15253756</PMID>
  </reference>
  <reference>
    <citation>Schoumans J, Ruivenkamp C, Holmberg E, Kyllerman M, Anderlid BM, Nordenskjöld M. Detection of chromosomal imbalances in children with idiopathic mental retardation by array based comparative genomic hybridisation (array-CGH). J Med Genet. 2005 Sep;42(9):699-705.</citation>
    <PMID>16141005</PMID>
  </reference>
  <reference>
    <citation>Fan YS, Jayakar P, Zhu H, Barbouth D, Sacharow S, Morales A, Carver V, Benke P, Mundy P, Elsas LJ. Detection of pathogenic gene copy number variations in patients with mental retardation by genomewide oligonucleotide array comparative genomic hybridization. Hum Mutat. 2007 Nov;28(11):1124-32.</citation>
    <PMID>17621639</PMID>
  </reference>
  <reference>
    <citation>Rosenberg C, Knijnenburg J, Bakker E, Vianna-Morgante AM, Sloos W, Otto PA, Kriek M, Hansson K, Krepischi-Santos AC, Fiegler H, Carter NP, Bijlsma EK, van Haeringen A, Szuhai K, Tanke HJ. Array-CGH detection of micro rearrangements in mentally retarded individuals: clinical significance of imbalances present both in affected children and normal parents. J Med Genet. 2006 Feb;43(2):180-6. Epub 2005 Jun 24.</citation>
    <PMID>15980116</PMID>
  </reference>
  <reference>
    <citation>Stankiewicz P, Beaudet AL. Use of array CGH in the evaluation of dysmorphology, malformations, developmental delay, and idiopathic mental retardation. Curr Opin Genet Dev. 2007 Jun;17(3):182-92. Epub 2007 Apr 30. Review.</citation>
    <PMID>17467974</PMID>
  </reference>
  <reference>
    <citation>Zung A, Rienstein S, Rosensaft J, Aviram-Goldring A, Zadik Z. Proximal 19q trisomy: a new syndrome of morbid obesity and mental retardation. Horm Res. 2007;67(3):105-10. Epub 2006 Oct 19.</citation>
    <PMID>17057406</PMID>
  </reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2009</study_first_submitted>
  <study_first_submitted_qc>January 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2010</study_first_posted>
  <last_update_submitted>June 13, 2012</last_update_submitted>
  <last_update_submitted_qc>June 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CGH array technology</keyword>
  <keyword>mental retardation</keyword>
  <keyword>chromosomal abnormalities</keyword>
  <keyword>syndromic obesity</keyword>
  <keyword>obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Intellectual Disability</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

